Top

European Journal of Nuclear Medicine and Molecular Imaging

Published in:

01-03-2012 | Review Article

Imaging the islet graft by positron emission tomography

Authors: Olof Eriksson, Abass Alavi

Published in: European Journal of Nuclear Medicine and Molecular Imaging | Issue 3/2012

Abstract

Clinical islet transplantation is being investigated as a permanent cure for type 1 diabetes mellitus (T1DM). Currently, intraportal infusion of islets is the favoured procedure, but several novel implantation sites have been suggested. Noninvasive longitudinal methodologies are an increasingly important tool for assessing the fate of transplanted islets, their mass, function and early signs of rejection. This article reviews the approaches available for islet graft imaging by positron emission tomography and progress in the field, as well as future challenges and opportunities.

Shapiro J. Eighty years after insulin: parallels with modern islet transplantation. CMAJ. 2002;167(12):1398–400.PubMed

Korsgren O, Nilsson B, Berne C, Felldin M, Foss A, Kallen R, et al. Current status of clinical islet transplantation. Transplantation. 2005;79(10):1289–93.PubMedCrossRef

Goto M, Eich TM, Felldin M, Foss A, Kallen R, Salmela K, et al. Refinement of the automated method for human islet isolation and presentation of a closed system for in vitro islet culture. Transplantation. 2004;78(9):1367–75.PubMedCrossRef

Shapiro AM, Lakey JR, Ryan EA, Korbutt GS, Toth E, Warnock GL, et al. Islet transplantation in seven patients with type 1 diabetes mellitus using a glucocorticoid-free immunosuppressive regimen. N Engl J Med. 2000;343(4):230–8.PubMedCrossRef

Rickels MR, Schutta MH, Markmann JF, Barker CF, Naji A, Teff KL. {beta}-Cell function following human islet transplantation for type 1 diabetes. Diabetes. 2005;54(1):100–6.PubMedCrossRef

Shapiro AM, Ricordi C, Hering BJ, Auchincloss H, Lindblad R, Robertson RP, et al. International trial of the Edmonton protocol for islet transplantation. N Engl J Med. 2006;355(13):1318–30.PubMedCrossRef

Bennet W, Sundberg B, Groth CG, Brendel MD, Brandhorst D, Brandhorst H, et al. Incompatibility between human blood and isolated islets of Langerhans: a finding with implications for clinical intraportal islet transplantation? Diabetes. 1999;48(10):1907–14.PubMedCrossRef

Moberg L, Johansson H, Lukinius A, Berne C, Foss A, Kallen R, et al. Production of tissue factor by pancreatic islet cells as a trigger of detrimental thrombotic reactions in clinical islet transplantation. Lancet. 2002;360(9350):2039–45.PubMedCrossRef

Johansson H, Lukinius A, Moberg L, Lundgren T, Berne C, Foss A, et al. Tissue factor produced by the endocrine cells of the islets of Langerhans is associated with a negative outcome of clinical islet transplantation. Diabetes. 2005;54(6):1755–62.PubMedCrossRef

10.

Hirshberg B, Montgomery S, Wysoki MG, Xu H, Tadaki D, Lee J, et al. Pancreatic islet transplantation using the nonhuman primate (rhesus) model predicts that the portal vein is superior to the celiac artery as the islet infusion site. Diabetes. 2002;51(7):2135–40.PubMedCrossRef

11.

Berney T, Toso C. Monitoring of the islet graft. Diabetes Metab. 2006;32(5 Pt 2):503–12.PubMedCrossRef

12.

Christoffersson G, Henriksnas J, Johansson L, Rolny C, Ahlstrom H, Caballero-Corbalan J, et al. Clinical and experimental pancreatic islet transplantation to striated muscle: establishment of a vascular system similar to that in native islets. Diabetes. 2010;59(10):2569–78.PubMedCrossRef

13.

Kallskog O, Kampf C, Andersson A, Carlsson PO, Hansell P, Johansson M, et al. Lymphatic vessels in pancreatic islets implanted under the renal capsule of rats. Am J Transplant. 2006;6(4):680–6.PubMedCrossRef

14.

Korsgren O, Nilsson B. Improving islet transplantation: a road map for a widespread application for the cure of persons with type I diabetes. Curr Opin Organ Transplant. 2009;14(6):683–7.PubMedCrossRef

15.

Perez VL, Caicedo A, Berman DM, Arrieta E, Abdulreda MH, Rodriguez-Diaz R, et al. The anterior chamber of the eye as a clinical transplantation site for the treatment of diabetes: a study in a baboon model of diabetes. Diabetologia. 2011;54(5):1121–6.PubMedCrossRef

16.

Leibiger IB, Caicedo A, Berggren PO. Non-invasive in vivo imaging of pancreatic beta-cell function and survival – a perspective. Acta Physiol (Oxf). 2011. doi:10.1111/j.1748-1716.2011.02301.x

17.

Kakabadze Z, Gupta S, Brandhorst D, Korsgren O, Berishvili E. Long-term engraftment and function of transplanted pancreatic islets in vascularized segments of small intestine. Transpl Int. 2011;24(2):175–83.PubMedCrossRef

18.

Paty BW, Bonner-Weir S, Laughlin MR, McEwan AJ, Shapiro AM. Toward development of imaging modalities for islets after transplantation: insights from the National Institutes of Health Workshop on Beta Cell Imaging. Transplantation. 2004;77(8):1133–7.PubMedCrossRef

19.

Toso C, Vallee JP, Morel P, Ris F, Demuylder-Mischler S, Lepetit-Coiffe M, et al. Clinical magnetic resonance imaging of pancreatic islet grafts after iron nanoparticle labeling. Am J Transplant. 2008;8(3):701–6.PubMedCrossRef

20.

Evgenov NV, Medarova Z, Dai G, Bonner-Weir S, Moore A. In vivo imaging of islet transplantation. Nat Med. 2006;12(1):144–8.PubMedCrossRef

21.

Medarova Z, Moore A. MRI as a tool to monitor islet transplantation. Nat Rev Endocrinol. 2009;5(8):444–52.PubMedCrossRef

22.

Toso C, Zaidi H, Morel P, Armanet M, Andres A, Pernin N, et al. Positron-emission tomography imaging of early events after transplantation of islets of Langerhans. Transplantation. 2005;79(3):353–5.PubMedCrossRef

23.

Eich T, Eriksson O, Sundin A, Estrada S, Brandhorst D, Brandhorst H, et al. Positron emission tomography: a real-time tool to quantify early islet engraftment in a preclinical large animal model. Transplantation. 2007;84(7):893–8.PubMedCrossRef

24.

Eich T, Eriksson O, Lundgren T. Visualization of early engraftment in clinical islet transplantation by positron-emission tomography. N Engl J Med. 2007;356(26):2754–5.PubMedCrossRef

25.

Eriksson O, Eich T, Sundin A, Tibell A, Tufveson G, Andersson H, et al. Positron emission tomography in clinical islet transplantation. Am J Transplant. 2009;9(12):2816–24.PubMedCrossRef

26.

Sweet IR, Cook DL, Lernmark A, Greenbaum CJ, Krohn KA. Non-invasive imaging of beta cell mass: a quantitative analysis. Diabetes Technol Ther. 2004;6(5):652–9.PubMedCrossRef

27.

Ichise M, Harris PE. Imaging of beta-cell mass and function. J Nucl Med. 2010;51(7):1001–4.PubMedCrossRef

28.

Harris PE, Ferrara C, Barba P, Polito T, Freeby M, Maffei A. VMAT2 gene expression and function as it applies to imaging beta-cell mass. J Mol Med. 2008;86(1):5–16.PubMedCrossRef

29.

Veluthakal R, Harris P. In vivo beta-cell imaging with VMAT 2 ligands – current state-of-the-art and future perspective. Curr Pharm Des. 2010;16(14):1568–81.PubMedCrossRef

30.

Anlauf M, Schafer MK, Schwark T, von Wurmb-Schwark N, Brand V, Sipos B, et al. Vesicular monoamine transporter 2 (VMAT2) expression in hematopoietic cells and in patients with systemic mastocytosis. J Histochem Cytochem. 2006;54(2):201–13.PubMedCrossRef

31.

Weihe E, Eiden LE. Chemical neuroanatomy of the vesicular amine transporters. FASEB J. 2000;14(15):2435–49.PubMedCrossRef

32.

Eiden LE. The vesicular neurotransmitter transporters: current perspectives and future prospects. FASEB J. 2000;14(15):2396–400.PubMedCrossRef

33.

Anlauf M, Eissele R, Schafer MK, Eiden LE, Arnold R, Pauser U, et al. Expression of the two isoforms of the vesicular monoamine transporter (VMAT1 and VMAT2) in the endocrine pancreas and pancreatic endocrine tumors. J Histochem Cytochem. 2003;51(8):1027–40.PubMedCrossRef

34.

Weihe E, Schafer MK, Erickson JD, Eiden LE. Localization of vesicular monoamine transporter isoforms (VMAT1 and VMAT2) to endocrine cells and neurons in rat. J Mol Neurosci. 1994;5(3):149–64.PubMedCrossRef

35.

Frey KA, Koeppe RA, Kilbourn MR. Imaging the vesicular monoamine transporter. Adv Neurol. 2001;86:237–47.PubMed

36.

Goland R, Freeby M, Parsey R, Saisho Y, Kumar D, Simpson N, et al. 11C-dihydrotetrabenazine PET of the pancreas in subjects with long-standing type 1 diabetes and in healthy controls. J Nucl Med. 2009;50(3):382–9.PubMedCrossRef

37.

Fagerholm V, Mikkola KK, Ishizu T, Arponen E, Kauhanen S, Nagren K, et al. Assessment of islet specificity of dihydrotetrabenazine radiotracer binding in rat pancreas and human pancreas. J Nucl Med. 2010;51(9):1439–46.PubMedCrossRef

38.

Simpson NR, Souza F, Witkowski P, Maffei A, Raffo A, Herron A, et al. Visualizing pancreatic beta-cell mass with [11C]DTBZ. Nucl Med Biol. 2006;33(7):855–64.PubMedCrossRef

39.

Eriksson O, Jahan M, Johnstrom P, Korsgren O, Sundin A, Halldin C, et al. In vivo and in vitro characterization of [18F]-FE-(+)-DTBZ as a tracer for beta-cell mass. Nucl Med Biol. 2010;37(3):357–63.PubMedCrossRef

40.

Kung MP, Hou C, Lieberman BP, Oya S, Ponde DE, Blankemeyer E, et al. In vivo imaging of beta-cell mass in rats using 18F-FP-(+)-DTBZ: a potential PET ligand for studying diabetes mellitus. J Nucl Med. 2008;49(7):1171–6.PubMedCrossRef

41.

Lin KJ, Weng YH, Wey SP, Hsiao IT, Lu CS, Skovronsky D, et al. Whole-body biodistribution and radiation dosimetry of 18F-FP-(+)-DTBZ (18F-AV-133): a novel vesicular monoamine transporter 2 imaging agent. J Nucl Med. 2010;51(9):1480–5.PubMedCrossRef

42.

Tsao HH, Lin KJ, Juang JH, Skovronsky DM, Yen TC, Wey SP, et al. Binding characteristics of 9-fluoropropyl-(+)-dihydrotetrabenazine (AV-133) to the vesicular monoamine transporter type 2 in rats. Nucl Med Biol. 2010;37(4):413–9.PubMedCrossRef

43.

Kwee TC, Basu S, Saboury B, Torigian DA, Naji A, Alavi A. Beta-cell imaging: opportunities and limitations. J Nucl Med. 2011;52(3):493; author reply 493–5.CrossRef

44.

Tornehave D, Kristensen P, Romer J, Knudsen LB, Heller RS. Expression of the GLP-1 receptor in mouse, rat, and human pancreas. J Histochem Cytochem. 2008;56(9):841–51.PubMedCrossRef

45.

Korner M, Stockli M, Waser B, Reubi JC. GLP-1 receptor expression in human tumors and human normal tissues: potential for in vivo targeting. J Nucl Med. 2007;48(5):736–43.PubMedCrossRef

46.

Gotthardt M, Fischer M, Naeher I, Holz JB, Jungclas H, Fritsch HW, et al. Use of the incretin hormone glucagon-like peptide-1 (GLP-1) for the detection of insulinomas: initial experimental results. Eur J Nucl Med Mol Imaging. 2002;29(5):597–606.PubMedCrossRef

47.

Wild D, Behe M, Wicki A, Storch D, Waser B, Gotthardt M, et al. [Lys40(Ahx-DTPA-111In)NH2]exendin-4, a very promising ligand for glucagon-like peptide-1 (GLP-1) receptor targeting. J Nucl Med. 2006;47(12):2025–33.PubMed

48.

Brom M, Oyen WJ, Joosten L, Gotthardt M, Boerman OC. 68Ga-labelled exendin-3, a new agent for the detection of insulinomas with PET. Eur J Nucl Med Mol Imaging. 2010;37(7):1345–55.PubMedCrossRef

49.

Wu Z, Todorov I, Li L, Bading J, Li Z, Nair I, et al. In vivo imaging of transplanted islets with (64)Cu-DO3A-VS-Cys(40)-exendin-4 by targeting GLP-1 receptor. Bioconjug Chem. 2011;22(8):1587–94.PubMedCrossRef

50.

Sweet IR, Cook DL, Lernmark A, Greenbaum CJ, Wallen AR, Marcum ES, et al. Systematic screening of potential beta-cell imaging agents. Biochem Biophys Res Commun. 2004;314(4):976–83.PubMedCrossRef

51.

Wangler B, Schneider S, Thews O, Schirrmacher E, Comagic S, Feilen P, et al. Synthesis and evaluation of (S)-2-(2-[18F]fluoroethoxy)-4-([3-methyl-1-(2-piperidin-1-yl-phenyl)-butyl-carbamoyl]-methyl)-benzoic acid ([18F]repaglinide): a promising radioligand for quantification of pancreatic beta-cell mass with positron emission tomography (PET). Nucl Med Biol. 2004;31(5):639–47.PubMedCrossRef

52.

Schmitz A, Shiue CY, Feng Q, Shiue GG, Deng S, Pourdehnad MT, et al. Synthesis and evaluation of fluorine-18 labeled glyburide analogs as beta-cell imaging agents. Nucl Med Biol. 2004;31(4):483–91.PubMedCrossRef

53.

Jager PL, Chirakal R, Marriott CJ, Brouwers AH, Koopmans KP, Gulenchyn KY. 6-L-18F-fluorodihydroxyphenylalanine PET in neuroendocrine tumors: basic aspects and emerging clinical applications. J Nucl Med. 2008;49(4):573–86.PubMedCrossRef

54.

Minn H, Kauhanen S, Seppanen M, Nuutila P. 18F-FDOPA: a multiple-target molecule. J Nucl Med. 2009;50(12):1915–8.PubMedCrossRef

55.

Garcia A, Mirbolooki MR, Constantinescu C, Pan ML, Sevrioukov E, Milne N, et al. 18F-Fallypride PET of pancreatic islets: in vitro and in vivo rodent studies. J Nucl Med. 2011;52(7):1125–32.PubMedCrossRef

56.

Koopmans KP, Neels OC, Kema IP, Elsinga PH, Sluiter WJ, Vanghillewe K, et al. Improved staging of patients with carcinoid and islet cell tumors with 18F-dihydroxy-phenyl-alanine and 11C-5-hydroxy-tryptophan positron emission tomography. J Clin Oncol. 2008;26(9):1489–95.PubMedCrossRef

57.

Witkowski P, Sondermeijer H, Hardy MA, Woodland DC, Lee K, Bhagat G, et al. Islet grafting and imaging in a bioengineered intramuscular space. Transplantation. 2009;88(9):1065–74.PubMedCrossRef

58.

Pattou F, Kerr-Conte J, Wild D. GLP-1-receptor scanning for imaging of human beta cells transplanted in muscle. N Engl J Med. 2010;363(13):1289–90.PubMedCrossRef

59.

Cabric S, Sanchez J, Johansson U, Larsson R, Nilsson B, Korsgren O, et al. Anchoring of vascular endothelial growth factor to surface-immobilized heparin on pancreatic islets: implications for stimulating islet angiogenesis. Tissue Eng Part A. 2010;16(3):961–70.PubMedCrossRef

60.

Cabric S, Sanchez J, Lundgren T, Foss A, Felldin M, Kallen R, et al. Islet surface heparinization prevents the instant blood-mediated inflammatory reaction in islet transplantation. Diabetes. 2007;56(8):2008–15.PubMedCrossRef

61.

Cabric S, Eich T, Sanchez J, Nilsson B, Korsgren O, Larsson R, et al. A new method for incorporating functional heparin onto the surface of islets of Langerhans. Tissue Eng Part C. 2008;14(2):141–7.CrossRef

62.

Najafi A, Peterson A. Preparation and in vitro evaluation of “no-carrier-added” 18F-labeled biotin. Nucl Med Biol. 1993;20(4):401–5.PubMedCrossRef

63.

Shoup TM, Fischman AJ, Jaywook S, Babich JW, Strauss HW, Elmaleh DR. Synthesis of fluorine-18-labeled biotin derivatives: biodistribution and infection localization. J Nucl Med. 1994;35(10):1685–90.PubMed

64.

Blom E, Langstrom B, Velikyan I. 68Ga-labeling of biotin analogues and their characterization. Bioconjug Chem. 2009;20(6):1146–51.PubMedCrossRef

65.

Min JJ, Gambhir SS. Molecular imaging of PET reporter gene expression. Handb Exp Pharmacol. 2008;185(2):277–303.PubMedCrossRef

66.

Gambhir SS, Barrio JR, Phelps ME, Iyer M, Namavari M, Satyamurthy N, et al. Imaging adenoviral-directed reporter gene expression in living animals with positron emission tomography. Proc Natl Acad Sci USA. 1999;96(5):2333–8.PubMedCrossRef

67.

Kim SJ, Doudet DJ, Studenov AR, Nian C, Ruth TJ, Gambhir SS, et al. Quantitative micro positron emission tomography (PET) imaging for the in vivo determination of pancreatic islet graft survival. Nat Med. 2006;12(12):1423–8.PubMedCrossRef

68.

Lu Y, Dang H, Middleton B, Zhang Z, Washburn L, Stout DB, et al. Noninvasive imaging of islet grafts using positron-emission tomography. Proc Natl Acad Sci USA. 2006;103(30):11294–9.PubMedCrossRef

69.

Lu Y, Dang H, Middleton B, Campbell-Thompson M, Atkinson MA, Gambhir SS, et al. Long-term monitoring of transplanted islets using positron emission tomography. Mol Ther. 2006;14(6):851–6.PubMedCrossRef

70.

Kim SJ, Nian C, Doudet DJ, McIntosh CH. Inhibition of dipeptidyl peptidase IV with sitagliptin (MK0431) prolongs islet graft survival in streptozotocin-induced diabetic mice. Diabetes. 2008;57(5):1331–9.PubMedCrossRef

71.

Yong J, Rasooly J, Dang H, Lu Y, Middleton B, Zhang Z, et al. Multimodality imaging of β-cells in mouse models of type 1 and 2 diabetes. Diabetes. 2011;60(5):1383–92.PubMedCrossRef

72.

Goldenberg DM, Sharkey RM. Novel radiolabeled antibody conjugates. Oncogene. 2007;26(25):3734–44.PubMedCrossRef

73.

Goldenberg DM, Rossi EA, Sharkey RM, McBride WJ, Chang CH. Multifunctional antibodies by the Dock-and-Lock method for improved cancer imaging and therapy by pretargeting. J Nucl Med. 2008;49(1):158–63.PubMedCrossRef

74.

Gruaz-Guyon A, Raguin O, Barbet J. Recent advances in pretargeted radioimmunotherapy. Curr Med Chem. 2005;12(3):319–38.PubMed

75.

Kudo T, Ueda M, Konishi H, Kawashima H, Kuge Y, Mukai T, et al. PET imaging of hypoxia-inducible factor-1-active tumor cells with pretargeted oxygen-dependent degradable streptavidin and a novel 18F-labeled biotin derivative. Mol Imaging Biol. 2010. doi:10.1007/s11307-010-0418-6.

76.

Eizirik DL, Colli ML, Ortis F. The role of inflammation in insulitis and beta-cell loss in type 1 diabetes. Nat Rev Endocrinol. 2009;5(4):219–26.PubMedCrossRef

77.

Barshes NR, Wyllie S, Goss JA. Inflammation-mediated dysfunction and apoptosis in pancreatic islet transplantation: implications for intrahepatic grafts. J Leukoc Biol. 2005;77(5):587–97.PubMedCrossRef

78.

Basu S, Zhuang H, Torigian DA, Rosenbaum J, Chen W, Alavi A. Functional imaging of inflammatory diseases using nuclear medicine techniques. Semin Nucl Med. 2009;39(2):124–45.PubMedCrossRef

79.

Kalliokoski T, Simell O, Haaparanta M, Viljanen T, Solin O, Knuuti J, et al. An autoradiographic study of [(18)F]FDG uptake to islets of Langerhans in NOD mouse. Diabetes Res Clin Pract. 2005;70(3):217–24.PubMedCrossRef

80.

Kalliokoski T, Nuutila P, Virtanen KA, Iozzo P, Bucci M, Svedstrom E, et al. Pancreatic glucose uptake in vivo in men with newly diagnosed type 1 diabetes. J Clin Endocrinol Metab. 2008;93(5):1909–14.PubMedCrossRef

81.

Bleeker-Rovers CP, Boerman OC, Rennen HJ, Corstens FH, Oyen WJ. Radiolabeled compounds in diagnosis of infectious and inflammatory disease. Curr Pharm Des. 2004;10(24):2935–50.PubMedCrossRef

82.

Paik JY, Lee KH, Byun SS, Choe YS, Kim BT. Use of insulin to improve [18F]fluorodeoxyglucose labelling and retention for in vivo positron emission tomography imaging of monocyte trafficking. Nucl Med Commun. 2002;23(6):551–7.PubMedCrossRef

83.

Eriksson O, Sadeghi A, Carlsson B, Eich T, Lundgren T, Nilsson B, et al. Distribution of adoptively transferred porcine T-lymphoblasts tracked by (18)F-2-fluoro-2-deoxy-d-glucose and position emission tomography. Nucl Med Biol. 2011;38(6):827–33.PubMedCrossRef

84.

Toso C, Zaidi H, Morel P, Armanet M, Wojtusciszyn A, Mai G, et al. Assessment of 18F-FDG-leukocyte imaging to monitor rejection after pancreatic islet transplantation. Transplant Proc. 2006;38(9):3033–4.PubMedCrossRef

Title: Imaging the islet graft by positron emission tomography
Authors: Olof Eriksson
Abass Alavi
Publication date: 01-03-2012
Publisher: Springer-Verlag
Published in: European Journal of Nuclear Medicine and Molecular Imaging / Issue 3/2012
Print ISSN: 1619-7070
Electronic ISSN: 1619-7089
DOI: https://doi.org/10.1007/s00259-011-1928-4

ACC 2024 Congress

Springer Medicine

Imaging the islet graft by positron emission tomography

Abstract

ACC 2024 Congress

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 3/2012

18F-radiolabeled analogs of exendin-4 for PET imaging of GLP-1 in insulinoma

Microvascular dysfunction in nonfailing arrhythmogenic right ventricular cardiomyopathy

Radiation dosimetry is a necessary ingredient for a perfectly mixed molecular radiotherapy cocktail

18F-FDG PET to identify soft tissue disease in multiple myeloma

Razelle Kurzrock, Maurie Markman (eds): Targeted Cancer Therapy

Prognostic significance of mediastinal 18F-FDG uptake in PET/CT in advanced ovarian cancer